Amardeep Shrestha, MD
Internal Medicine · O Fallon, ILNPI 1730490525
Payments from drug & device makers
Across 62 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$218
- Novo Nordisk$171
- Lilly USA, LLC$142
- AbbVie$125
- Boehringer Ingelheim$100
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$71
- plus $378 from 14 others
What the payments were for
- Food & beverage$1,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $218 |
| Novo Nordisk | 7 | $171 |
| Lilly USA, LLC | 7 | $142 |
| AbbVie | 7 | $125 |
| Boehringer Ingelheim | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Dexcom, Inc. | 4 | $63 |
| Amgen | 3 | $54 |
| Optinose US, Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Exact Sciences | 1 | $26 |
| Optos, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
How this compares
$1,203 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $152,003 |
| JardianceEmpagliflozin | 78 | $100,751 |
| EliquisApixaban | 51 | $44,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $33,938 |
| JanuviaSitagliptin Phosphate | 19 | $33,921 |
| FarxigaDapagliflozin Propanediol | 34 | $32,473 |
| TrulicityDulaglutide | 30 | $29,690 |
| XareltoRivaroxaban | 26 | $24,635 |
| Spiriva RespimatTiotropium Bromide | 29 | $22,255 |
| LinzessLinaclotide | 20 | $17,073 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| MounjaroTirzepatide | 11 | $12,278 |
| MovantikNaloxegol Oxalate | 17 | $9,913 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 27 | $8,432 |
| Xtampza ErOxycodone Myristate | 11 | $7,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $171 | $152,003125 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $100 | $123,006107 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $218 | $45,86863 claims |
| PfizerEliquis | $15 | $44,31151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $142 | $41,96841 claims |
| AbbVieLinzess, Vraylar | $125 | $33,07331 claims |
| Johnson & JohnsonXarelto | $37 | $24,63526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in O Fallon
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.